



**Title (Maximum 18 words – Title case ,Font type : Nirmala UI , Font size 14 pt)**

**First Author Name<sup>1</sup>, Second Author Name<sup>2\*</sup>, Third Author Name (Cambria, Bold, 12 pt)**

<sup>1</sup>Faculty of XXX, University XXX, Address XXX, Postal Code, Country (Cambria, 10 pt)

<sup>2</sup>Department of XXX, Address XXX, Postal Code, Country (Cambria, 10 pt)

<sup>3</sup>Laboratory of XXX, Address XXX, Postal Code, Country (Cambria, 10 pt)



<https://doi.org/xxxxxxx> (filled by editor)



J. Pharm. Sci. Community, YYYY, Vol (No), page

#### Article Info

**Received:** DD-MM-YYYY

**Revised:** DD-MM-YYYY

**Accepted:** DD-MM-YYYY

**\*Corresponding author:**

Name of corresponding author (Cambria, 10 pt)

email: email of

corresponding author

(Cambria, 10 pt)

**Keywords:**

Keyword 1; keyword 2;

keyword 3; keyword 4;

keyword 5 (Cambria, 10 pt,  
alphabetically ordered)

#### ABSTRACT

Abstract should be wrote in one paragraph as a summary of the article with maximum of 200 words. The font type is Cambria 10 pt and single space. The abstract should contain background, objectives, methodology, results, and brief conclusions. The abstract should not contain tables/images. Abstract should be accurate, brief, clear, specific, and avoided from non-standard or uncommon abbreviations.

#### INTRODUCTION (Cambria, Bold, 10 pt)

Manuscripts are written with Cambria 10 pt, 1 (one) columns, 1 space density on space density, on A4 paper with a top-left margin of 3 cm and bottom-right 2.5 cm. First line indentation in each paragraph is 1.27 cm.

The number of paragraphs is not limited, but the contents must include the background, the aim of the research, the position of the research on previous research activities, and the novelty of the research. A theoretical foundation that directly related to the content of the article can be included but does not need to be made a separate sub-chapter. Introduction section should be avoided from a detailed literature survey or a summary of the results.

#### METHODS (Cambria, Bold, 10 pt)

Manuscripts are written with Cambria 10 pt, 1 (one) columns, 1 space density on space density, on A4 paper with a top-left margin of 3 cm and bottom-right 2.5 cm. First line indentation in each paragraph is 1.27 cm.

This section provide clear information of materials, instrumentations, and methods used in order to allow the work to be reproduced by the readers. Methods already published should be indicated by a reference: only relevant modifications should be described. For the chemicals, authors should provide details of brand and purity, for example: ammonia 25% (Merck Millipore). For the

instrument, the author should provide information on the brand and type. If the instrument is a modification, then information about the modifications made is required.

### **RESULTS AND DISCUSSION (Cambria, Bold, 10 pt)**

Manuscripts are written with Cambria 10 pt, 1 (one) columns, 1 space density on space density, on A4 paper with a top-left margin of 3 cm and bottom-right 2.5 cm. First line indentation in each paragraph is 1.27 cm. The results should be clear and concise of summarizing (scientific) findings rather than providing data in great detail. The discussion should explore the significance of the results of the work. Avoid extensive citations and discussion of published literature.

The explanations and information regarding tables and/or figures must state the number of the table/figure being referred to. The research results in the form of tables/pictures are placed at the end of the manuscript after the reference (not placed in the results and discussion).

### **CONCLUSIONS (Cambria, Bold, 10 pt)**

The main conclusions of the study should be presented in a short Conclusions section. Conclusions should answer the objectives of research. In this section, authors could also suggest future experiments and/or point out those that are underway. (Cambria, 10 pt)

### **ACKNOWLEDGEMENTS (Cambria, Bold, 10 pt)**

Advisors, financial supporters, or other supporters i.e. proofreaders, typists, and suppliers who have assisted authors in the research can be listed in this section. (Cambria 10 pt)

### **CONFLICT OF INTEREST (Cambria, Bold, 10 pt)**

If there are conflict of interest, it should be state clearly. Financial and personal relationships should be easily identifiable, leading to bias in work. The sources of funding for the work should be described explicitly with explanations of the roles of those sources, and the authors should state that the sources of support do not participate in specific roles. The authors should state that the authors have access to all the studies and that the sponsors have not interacted with the data or the work. Conversely, if the authors do not have a conflict of interest, they may find them expressly stately. (Cambria, 10 pt)

### **REFERENCES (Cambria, Bold, 10 pt)**

The references used should be up to date (maximum of 10 years) and dominated of journal articles (at least 80%). It is highly recommended to use the reference manager to organize the references such as Zotero, Mendeley, Endnote, etc. The reference style used can be found in <https://tinyurl.com/jpsc-csl>. If you are a Mendeley user, you can install the journal's reference style by accessing <https://csl.mendeley.com/styles/28740611/journal-of-pharmaceutical-sciences-and-community>.

#### **Book**

Miller, J.N., Miller, J.C., Miller, R.D., 2018. Statistics and Chemometrics for Analytical Chemistry, Seventh Ed. ed. Pearson Education Limited, Harlow.

#### **Book Chapters**

Allen, L.V, Ansel, H.C., 2014. Section II. Drug dosage form and drug delivery system design. Chapter 4. Dosage form design: Pharmaceutical and formulation consideration, in: Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Tenth Ed. pp. 102–165.

#### **Conference proceeding**

Istyastono, E.P., Yuliani, S.H., 2016. Scarless wound healing gel with Binahong (*Anredera cordifolia* (Ten) Steenis) leaves extract and celecoxib as the active ingredients, in: AIP Conference Proceedings. p. 160001.

#### **Journal Article**

Riswanto, F.D.O., Windarsih, A., Lukitaningsih, E., Rafi, M., Fadzilah, N.A., Rohman, A., 2022. Metabolite Fingerprinting Based on <sup>1</sup>H-NMR Spectroscopy and Liquid Chromatography for the Authentication of Herbal Products. *Molecules*, 27(1198), 1–17.

#### **Guidelines**

Tunkel, D.E., Bauer, C.A., Sun, G.H., Rosenfeld, R.M., Chandrasekhar, S.S., Cunningham, E.R., Archer, S.M., Blakley, B.W., Carter, J.M., Granieri, E.C., Henry, J.A., Hollingsworth, D., Khan, F.A., Mitchell, S., Monfared, A., Newman, C.W., Omole, F.S., Phillips, C.D., Robinson, S.K., Taw, M.B., Tyler, R.S., Waguespack, R., Whamond, E.J., 2014. Clinical practice guideline: Tinnitus. *Otolaryngology - Head and Neck Surgery (United States)*.


**Online**

Narkhede, S., 2018. Understanding AUC - ROC Curve [WWW Document]. Towards Data Science. URL <https://towardsdatascience.com/understanding-auc-r> (accessed 9.11.20).

**TABLE AND FIGURES**

All illustrations including figures, charts and graphs should be clear with minimum resolution of 300 dpi. The caption must be placed below and numbered (1, 2, 3 etc.). Use the bold font of the figure caption (e.g. **Figure 1**. Structures of isoflavones found in ethanolic extract).

All the tables should be prepared using the horizontal border style only (without vertical border). The caption must be placed above and numbered (1, 2, 3 etc.). Use the bold font of the table caption (e.g. **Table 1**. Characteristics of Health Facilities at Some Hospitals in Yogyakarta). If necessary, footnote should be placed below the table, with smaller font size of the table font (Cambria font with size of 9). Each figure should be supplied on separate pages with number according to appearance on the text.

**Examples:**

**Figure 1.** Total quantity of antibiotics used at the hospital each year over five-year-period of 2013 – 2017

**Table 1.** Characteristics of patients in the period January-December 2019

Characteristics of Patients	Patients (n= 124)	
	n	%
Gender		
Male	52	41.94
Female	72	58.06
Hypertensive therapy		
Mono therapy	107	86.29
>1 therapy	17	13.71
Mean blood pressure (mmHg)*		
Systolic blood pressure (mmHg)	136.33 ± 14.26	
Diastolic blood pressure (mmHg)	84.04 ± 8.35	
Mean age (years)*	55.92 ± 11.88	
Mean duration of the disease (years)*	6.10 ± 2.71	
Mean MPR value*	0.59 ± 0.31	

\*numeric data presented as mean±SD, standard deviation